Gene

Synthetic DNA Delivers a Sustainable Future for Genetic Medicines

Touchlight

Nonviral Delivery

Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery using dbDNA

Lisa Caproni

Touchlight

Biotech

Five Small Biotechs to Watch: October 2024

David Alvaro, Ph.D.

Pharma's Almanac

dbDNA

Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA

Jill Makin

Touchlight

Plasmid Manufacturing

Optimizing Plasmid Production to Meet Growing Demand

Cynthia A. Challener, Ph.D.; Danielle Alvarez

Pharma's Almanac

AAV Capsid Engineering

Expanding Patient Access to Gene Therapies through AAV Capsid Engineering

Damien Marsic, Ph.D.

Porton Advanced Solutions

Column: M&A

Why the Big Shifts in Gene Therapy Investments? It’s Late in the Game

Nigel Walker

Nice Insight

Gene Therapy Analytics

Overcoming Analytical Challenges for Gene Therapies

Jennifer Chadwick, Ph.D.

ProtaGene

Viral Vector Manufacturing

Optimizing Yields, Tech Transfer, and the Supply Chain for Viral Vector Manufacturing

Andrew Moreo; Lenore Giannunzio

Andelyn Biosciences

Gene Therapy

Changing Lives, One Patient at a Time

Andelyn Biosciences

2021 Roundup: The Year of Cell and Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Gene Therapy

A Customer-Centric Approach to Cell and Gene Therapy Manufacturing

Drew Brennan

Avid Bioservices

Viral Vectors

Navigating Analytical Requirements for GMP Viral Vectors

Will Fountain

Andelyn Biosciences

Gene Therapy

Building a Bridge of Equivalence to Facilitate and Implement Rapid Process Changes in Gene Therapy Manufacturing

Wade Macedone; Jonathan Rush; Phillip Vermilion; Samir Acharya, Ph.D.

Andelyn Biosciences

Gene Therapy

Pandemic Playbook for Gene Therapy Manufacturing

Ratish Krishnan; David Loong, Ph.D.; Nargisse El-Hajjami, Ph.D.

MilliporeSigma